ALX Oncology 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   4 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evorpacept (ALX148) / ALX Oncology
2021-001008-14: A Study of ALX148 in Patients with Advanced Gastric Cancer

Not yet recruiting
2/3
472
RoW, Europe
Evorpacept, Trastuzumab, CYRAMZA, Paclitaxel, ALX148, Ramucirumab, Solution for infusion, Powder for concentrate for solution for injection/infusion, Concentrate for solution for infusion, Herceptin, CYRAMZA, Paclitaxel 6mg/ml concentrate for solution for infusion
ALX Oncology Inc., ALX ONCOLOGY INC, ALX Oncology Inc.
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)., Patients with advanced gastric cancers who have failed prior treatment regimens., Diseases [C] - Digestive System Diseases [C06]
 
 
ASPEN-06, NCT05002127 / 2021-001008-14: A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer

Jul 2023 - Dec 2023: Data from ASPEN-06 trial for advanced HER2+ gastric cancer
Hourglass Jan 2023 - Dec 2023 : Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML
Recruiting
2/3
450
Europe, Japan, US, RoW
Evorpacept (ALX148), Trastuzumab, Herceptin, Ramucirumab, Cyramza, Paclitaxel, Taxol
ALX Oncology Inc., Eli Lilly and Company
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
07/26
08/28
2020-004662-19: A trial in patients with advanced head and neck cancer looking at combining ALX148, pembrolizumab and chemotherapy

Not yet recruiting
2
162
Europe
Evorpacept, Pembrolizumab, Cisplatin, Carboplatin, Fluorouracil, ALX148, Solution for injection, Concentrate for solution for infusion, Keytruda, Cisplatin, Carboplatin, Fluorouracil
ALX Oncology Inc., ALX Oncology Inc.
Patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease, Head and neck cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-B87, NCT04675294 / 2020-004093-21: Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Jun 2024 - Dec 2024: Data from ASPEN-03 trial in combination with Keytruda for advanced HNSCC
Active, not recruiting
2
189
Europe, Canada, US, RoW
evorpacept, ALX148, pembrolizumab, KEYTRUDA®
ALX Oncology Inc., Merck Sharp & Dohme LLC
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
06/25
12/25
KEYNOTE-B88, NCT04675333 / 2020-004662-19: Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Jul 2024 - Dec 2024: Data from ASPEN-04 trial in combination with Keytruda and chemotherapy for advanced HNSCC
Active, not recruiting
2
172
Europe, US, RoW
evorpacept, ALX148, pembrolizumab, KEYTRUDA®, Cisplatin/Carboplatin; 5FU, Platinol/Paraplatin; Adrucil
ALX Oncology Inc., Merck Sharp & Dohme LLC
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
06/25
12/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
NCT05787639: Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Recruiting
2
29
US
Evorpacept, ALX 148
University of California, San Diego
Oropharynx Cancer
08/26
05/28
NCT05467670: Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Recruiting
2
31
US
Pembrolizumab, Keytruda®, ALX148, evorpacept, Doxorubicin, (Pegylated Liposomal Doxorubicin (PLD)
Alexander B Olawaiye, MD, ALX Oncology, Merck Sharp & Dohme LLC
Ovarian Cancer
09/29
12/31
ASPEN-02, NCT04417517 / 2021-000705-25: A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome

Jul 2023 - Dec 2023: Presentation of data from P1b portion of P1/2 ASPEN-02 trial in combination with azacitidine for the treatment of MDS
Checkmark Final data from ASPEN-02 trial in combination with azacitidine for high-risk MDS at ASH 2021
Dec 2021 - Dec 2021: Final data from ASPEN-02 trial in combination with azacitidine for high-risk MDS at ASH 2021
Checkmark Presentation of data from ASPEN-02 study in combination with azacitidine for the treatment of MDS
Nov 2021 - Nov 2021: Presentation of data from ASPEN-02 study in combination with azacitidine for the treatment of MDS
Active, not recruiting
1/2
65
Europe, US, RoW
evorpacept, ALX148, azacitidine, Vidaza
ALX Oncology Inc.
Higher Risk Myelodysplastic Syndromes
12/23
06/24
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
NCT05025800: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
1/2
47
US
CD47 Antagonist ALX148, ALX 148, ALX-148, ALX148, CD47/SIRPa-blocking Agent ALX148, SIRPa Variant ALX148, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
03/26
03/26
NCT04643002 / 2020-003024-16: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
1/2
258
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148
Sanofi
Plasma Cell Myeloma Refractory
09/27
04/28
ASPEN-01, NCT03013218: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma

Hourglass Jan 2024 - Jun 2024 : Results from ASPEN-01 trial for NHL
Checkmark FDA granted Fast Track designation in combination with KEYTRUDA for adult patient with 1L HNSCC
Aug 2022 - Aug 2022: FDA granted Fast Track designation in combination with KEYTRUDA for adult patient with 1L HNSCC
Checkmark Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
Nov 2021 - Nov 2021: Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
More
Active, not recruiting
1
174
US, RoW
Evorpacept (ALX148), Pembrolizumab, Trastuzumab, Rituximab, Ramucirumab + Paclitaxel, 5-FU + Cisplatin
ALX Oncology Inc.
Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
02/22
12/24
ASPEN-05, NCT04755244: A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia

Hourglass Jan 2023 - Dec 2023 : Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML
Checkmark Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Checkmark Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
More
Terminated
1
14
US
evorpacept, ALX148, venetoclax, Venclexta, azacitidine, Vidaza
ALX Oncology Inc.
Acute Myeloid Leukemia, AML, Adult
05/23
08/23
ASPEN-07, NCT05524545: A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma

Recruiting
1
30
US
Evorpacept, ALX148, Enfortumab Vedotin, PADCEV
ALX Oncology Inc.
Bladder Cancer, Urothelial Carcinoma
12/24
04/25
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
124
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Ziihera, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/28
12/29
ALTA-002 / ALX Oncology, Tallac Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evorpacept (ALX148) / ALX Oncology
2021-001008-14: A Study of ALX148 in Patients with Advanced Gastric Cancer

Not yet recruiting
2/3
472
RoW, Europe
Evorpacept, Trastuzumab, CYRAMZA, Paclitaxel, ALX148, Ramucirumab, Solution for infusion, Powder for concentrate for solution for injection/infusion, Concentrate for solution for infusion, Herceptin, CYRAMZA, Paclitaxel 6mg/ml concentrate for solution for infusion
ALX Oncology Inc., ALX ONCOLOGY INC, ALX Oncology Inc.
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)., Patients with advanced gastric cancers who have failed prior treatment regimens., Diseases [C] - Digestive System Diseases [C06]
 
 
ASPEN-06, NCT05002127 / 2021-001008-14: A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer

Jul 2023 - Dec 2023: Data from ASPEN-06 trial for advanced HER2+ gastric cancer
Hourglass Jan 2023 - Dec 2023 : Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML
Recruiting
2/3
450
Europe, Japan, US, RoW
Evorpacept (ALX148), Trastuzumab, Herceptin, Ramucirumab, Cyramza, Paclitaxel, Taxol
ALX Oncology Inc., Eli Lilly and Company
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
07/26
08/28
2020-004662-19: A trial in patients with advanced head and neck cancer looking at combining ALX148, pembrolizumab and chemotherapy

Not yet recruiting
2
162
Europe
Evorpacept, Pembrolizumab, Cisplatin, Carboplatin, Fluorouracil, ALX148, Solution for injection, Concentrate for solution for infusion, Keytruda, Cisplatin, Carboplatin, Fluorouracil
ALX Oncology Inc., ALX Oncology Inc.
Patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease, Head and neck cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-B87, NCT04675294 / 2020-004093-21: Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Jun 2024 - Dec 2024: Data from ASPEN-03 trial in combination with Keytruda for advanced HNSCC
Active, not recruiting
2
189
Europe, Canada, US, RoW
evorpacept, ALX148, pembrolizumab, KEYTRUDA®
ALX Oncology Inc., Merck Sharp & Dohme LLC
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
06/25
12/25
KEYNOTE-B88, NCT04675333 / 2020-004662-19: Evorpacept (ALX148) in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Jul 2024 - Dec 2024: Data from ASPEN-04 trial in combination with Keytruda and chemotherapy for advanced HNSCC
Active, not recruiting
2
172
Europe, US, RoW
evorpacept, ALX148, pembrolizumab, KEYTRUDA®, Cisplatin/Carboplatin; 5FU, Platinol/Paraplatin; Adrucil
ALX Oncology Inc., Merck Sharp & Dohme LLC
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
06/25
12/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
NCT05787639: Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

Recruiting
2
29
US
Evorpacept, ALX 148
University of California, San Diego
Oropharynx Cancer
08/26
05/28
NCT05467670: Safety and Efficacy of Anti-CD47, ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Recruiting
2
31
US
Pembrolizumab, Keytruda®, ALX148, evorpacept, Doxorubicin, (Pegylated Liposomal Doxorubicin (PLD)
Alexander B Olawaiye, MD, ALX Oncology, Merck Sharp & Dohme LLC
Ovarian Cancer
09/29
12/31
ASPEN-02, NCT04417517 / 2021-000705-25: A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome

Jul 2023 - Dec 2023: Presentation of data from P1b portion of P1/2 ASPEN-02 trial in combination with azacitidine for the treatment of MDS
Checkmark Final data from ASPEN-02 trial in combination with azacitidine for high-risk MDS at ASH 2021
Dec 2021 - Dec 2021: Final data from ASPEN-02 trial in combination with azacitidine for high-risk MDS at ASH 2021
Checkmark Presentation of data from ASPEN-02 study in combination with azacitidine for the treatment of MDS
Nov 2021 - Nov 2021: Presentation of data from ASPEN-02 study in combination with azacitidine for the treatment of MDS
Active, not recruiting
1/2
65
Europe, US, RoW
evorpacept, ALX148, azacitidine, Vidaza
ALX Oncology Inc.
Higher Risk Myelodysplastic Syndromes
12/23
06/24
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
NCT05025800: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
1/2
47
US
CD47 Antagonist ALX148, ALX 148, ALX-148, ALX148, CD47/SIRPa-blocking Agent ALX148, SIRPa Variant ALX148, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
M.D. Anderson Cancer Center
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
03/26
03/26
NCT04643002 / 2020-003024-16: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Recruiting
1/2
258
Europe, US, RoW
Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148
Sanofi
Plasma Cell Myeloma Refractory
09/27
04/28
ASPEN-01, NCT03013218: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma

Hourglass Jan 2024 - Jun 2024 : Results from ASPEN-01 trial for NHL
Checkmark FDA granted Fast Track designation in combination with KEYTRUDA for adult patient with 1L HNSCC
Aug 2022 - Aug 2022: FDA granted Fast Track designation in combination with KEYTRUDA for adult patient with 1L HNSCC
Checkmark Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
Nov 2021 - Nov 2021: Data from ASPEN-01 trial in combination with Keytruda for HNSCC at SITC 2021
More
Active, not recruiting
1
174
US, RoW
Evorpacept (ALX148), Pembrolizumab, Trastuzumab, Rituximab, Ramucirumab + Paclitaxel, 5-FU + Cisplatin
ALX Oncology Inc.
Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
02/22
12/24
ASPEN-05, NCT04755244: A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia

Hourglass Jan 2023 - Dec 2023 : Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML
Checkmark Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Checkmark Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
More
Terminated
1
14
US
evorpacept, ALX148, venetoclax, Venclexta, azacitidine, Vidaza
ALX Oncology Inc.
Acute Myeloid Leukemia, AML, Adult
05/23
08/23
ASPEN-07, NCT05524545: A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma

Recruiting
1
30
US
Evorpacept, ALX148, Enfortumab Vedotin, PADCEV
ALX Oncology Inc.
Bladder Cancer, Urothelial Carcinoma
12/24
04/25
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
124
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Ziihera, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/28
12/29
ALTA-002 / ALX Oncology, Tallac Therap
No trials found

Download Options